BioNexus Gene Lab (BGLC) Other Operating Expenses (2024 - 2026)

BioNexus Gene Lab (BGLC) has 3 years of Other Operating Expenses data on file, last reported at $216984.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 15.71% year-over-year to $216984.0; the trailing twelve-month figure through Mar 2026 stood at -$961162.0 (down 133.67% YoY), and the FY2025 full-year result was -$324836.0, down 126.58% from the prior year.
• Other Operating Expenses rose to $216984.0 in Q1 2026, from -$1.0 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $2.6 million in Q4 2024 to a low of -$1.3 million in Q1 2024.
• A 3-year average of $67125.0 and a median of $216984.0 in 2026 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 119.97% in 2025, while the deepest fall reached 139.37% in 2025.
• Tracing BGLC's Other Operating Expenses over 3 years: stood at $2.6 million in 2024, then slumped by 139.37% to -$1.0 million in 2025, then surged by 121.56% to $216984.0 in 2026.
• Business Quant data shows BGLC's Other Operating Expenses at $216984.0 in Q1 2026, -$1.0 million in Q4 2025, and $281696.0 in Q3 2025.